Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin Treatment

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 136 participants.

Also called NCT02967237

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 136 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02967237
  • EudraCT 2015-002416-33
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
France (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02967237. Allocation not applicable; no masking; primary purpose treatment. Start 2016-01-04 (registry gives no type); primary completion 2017-07-24 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin Treatment
Acronym
Transition II
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
insulin glargine (U300)
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct02967237
Content hash
ea4414a24a855737be37805ede423174c3ef44a82798ea6cad066000756beeb1